Prof Geiger’s expertise lies in the organization of pharmaceutical markets and the role of the public good in these markets, for instance in issues of pricing, patenting, and access to medicines. She was recently appointed as a member of the WHO Technical Advisory Group on pharmaceutical pricing policies. She is the only female holder in an Irish Business School of a highly prestigious ERC Consolidator Grant (2018-2024). Prof Geiger has held other prestigious grants in the past, and she has been a Visiting Professor at some of the most highly-ranked Universities globally, including the University of California Berkeley, Stockholm School of Economics, Ecole de Mines Paris, SciencesPo Paris, University of Auckland and University of Vienna. Her work has been published widely in highly ranked journals and policy outlets. Her latest monograph entitled “Peak Pharma” will be published by Oxford University Press in early 2025.